We hereby submit Audited Financial Results Q4 and FY2026
YATHARTH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.7 pts less than Nifty Microcap 250 and 5.6 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Yatharth Hospital reported strong FY2026 results with consolidated revenue growing 36% to Rs 12,072 million from Rs 8,856 million in FY2025. Consolidated profit after tax rose 30% to Rs 1,703 million from Rs 1,306 million. The company expanded its hospital network with three new facilities - a 300-bed hospital in New Delhi (started July 2025), a 400-bed hospital in Faridabad (started September 2025), and a 150-bed hospital in Agra (started February 2026). Standalone revenue grew 30% to Rs 5,919 million while PAT grew 9% to Rs 954 million. The Income Tax Department had issued assessment orders which the company has appealed, believing no material liability is expected. Auditors MSKA & Associates LLP gave unmodified opinions on both standalone and consolidated financial statements.
The company delivered robust revenue and profit growth driven by organic expansion and new hospital acquisitions. The EBITDA margin compression reflects higher operating costs from new facility ramp-ups. The stock is likely to be viewed positively given strong top-line growth and PAT expansion exceeding 25% on consolidated basis.